Literature DB >> 21193494

Influence of genospecies of Acinetobacter baumannii complex on clinical outcomes of patients with acinetobacter bacteremia.

Yu-Chung Chuang1, Wang-Huei Sheng, Shu-Ying Li, Yu-Chi Lin, Jann-Tay Wang, Yee-Chun Chen, Shan-Chwen Chang.   

Abstract

BACKGROUND: acinetobacter baumannii complex infections are increasing in prevalence and are associated with a high mortality. Biochemical classification tests cannot differentiate A. baumannii (genospecies 2) from other genospecies. Genospecies typing offers a potential tool to determine whether there are major differences in pathogenicity among the genospecies.
METHODS: adult patients with A. baumannii complex bacteremia in intensive care units were prospectively observed from January 2007 through July 2009. A. baumannii complex was identified by biochemical methods and the Phoenix bacterial identification system. Genospecies were identified by 16S-23S ribosomal RNA intergenic-spacer sequencing.
RESULTS: among the 135 patients with A. baumannii complex bacteremia, 87 (64.4%) had isolates that belonged to genospecies 2, 36 (26.7%) had isolates that belonged to genospecies 13TU, and 12 (8.9%) had isolates that belonged to genospecies 3. Patients with A. baumannii (genospecies 2) bacteremia were more likely to have pneumonia than were patients with bacteremia due to genospecies 13TU (63.2 % vs 27.8%; P =.001), whereas patients with bacteremia due to genospecies 13TU were more likely to have primary bacteremia (69.4% vs 20.7%; P <.001). Genospecies 2 was less susceptible to antibiotics than were other genospecies. It was associated with a higher rate of mortality than was genospecies 13TU (58.6% vs 16.7%; P < .001). On multivariate analysis, genospecies 2 was an independent predictor of mortality (odds ratio, 5.46; 95% confidence interval, 2.00-14.91; P = .001).
CONCLUSIONS: genospecies 2 of the A. baumannii complex was associated with greater resistance to antibiotics and higher mortality among bacteremic patients, compared with other genospecies, especially genospecies 13TU. These findings emphasize the need to focus on genospecies to better understand the pathogenesis and epidemiology of infections caused by the A. baumannii complex.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21193494     DOI: 10.1093/cid/ciq154

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  50 in total

1.  Draft genome sequence of an Acinetobacter genomic species 3 strain harboring a bla(NDM-1) gene.

Authors:  Yong Chen; Yujun Cui; Fei Pu; Guoqin Jiang; Xiangna Zhao; Yanting Yuan; Wei Zhao; Dongfang Li; Hui Liu; Yin Li; Ting Liang; Li Xu; Yan Wang; Qing Song; Jiyong Yang; Long Liang; Ruifu Yang; Li Han; Yajun Song
Journal:  J Bacteriol       Date:  2012-01       Impact factor: 3.490

Review 2.  Acinetobacter baumannii: evolution of antimicrobial resistance-treatment options.

Authors:  Yohei Doi; Gerald L Murray; Anton Y Peleg
Journal:  Semin Respir Crit Care Med       Date:  2015-02-02       Impact factor: 3.119

3.  Identification, genotypic relation, and clinical features of colistin-resistant isolates of Acinetobacter genomic species 13BJ/14TU from bloodstreams of patients in a university hospital.

Authors:  Seung Yeob Lee; Jong Hee Shin; Kyung Hwa Park; Ju Hee Kim; Myung Geun Shin; Soon Pal Suh; Dong Wook Ryang; Soo Hyun Kim
Journal:  J Clin Microbiol       Date:  2014-01-08       Impact factor: 5.948

4.  Outer membrane Protein A plays a role in pathogenesis of Acinetobacter nosocomialis.

Authors:  Sang Woo Kim; Man Hwan Oh; So Hyun Jun; Hyejin Jeon; Seung Il Kim; Kwangho Kim; Yoo Chul Lee; Je Chul Lee
Journal:  Virulence       Date:  2016-01-13       Impact factor: 5.882

5.  Efficacy of tigecycline for secondary Acinetobacter bacteremia and factors associated with treatment failure.

Authors:  Bo-Huang Liou; Yi-Tzu Lee; Shu-Chen Kuo; Po-Yu Liu; Chang-Phone Fung
Journal:  Antimicrob Agents Chemother       Date:  2015-03-30       Impact factor: 5.191

6.  Diverse responses to UV light exposure in Acinetobacter include the capacity for DNA damage-induced mutagenesis in the opportunistic pathogens Acinetobacter baumannii and Acinetobacter ursingii.

Authors:  Janelle M Hare; James A Bradley; Ching-Li Lin; Tyler J Elam
Journal:  Microbiology       Date:  2011-11-24       Impact factor: 2.777

7.  Utility of Whole-Genome Sequencing in Characterizing Acinetobacter Epidemiology and Analyzing Hospital Outbreaks.

Authors:  Margaret A Fitzpatrick; Egon A Ozer; Alan R Hauser
Journal:  J Clin Microbiol       Date:  2015-12-23       Impact factor: 5.948

8.  Phenotypic and molecular characterization of Acinetobacter clinical isolates obtained from inmates of California correctional facilities.

Authors:  Galarah D Golanbar; Christopher K Lam; Yi-Ming Chu; Carla Cueva; Stephanie W Tan; Isba Silva; H Howard Xu
Journal:  J Clin Microbiol       Date:  2011-03-30       Impact factor: 5.948

Review 9.  Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infections.

Authors:  J Alexander Viehman; M Hong Nguyen; Yohei Doi
Journal:  Drugs       Date:  2014-08       Impact factor: 9.546

10.  Influence of ACB complex genospecies on clinical outcomes in a U.S. hospital with high rates of multidrug resistance.

Authors:  Margaret A Fitzpatrick; Egon Ozer; Maureen K Bolon; Alan R Hauser
Journal:  J Infect       Date:  2014-09-19       Impact factor: 6.072

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.